European Heart Journal

In the current paper, we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptiide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward. We have also included relevant articles related to cardiovascular disease prevention in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.

خرید پکیج و مشاهده آنلاین مقاله

The year in cardiovascular medicine 2021: digital health and innovation

Panos E. Vardas, Folkert W. Asselbergs, Maarten van Smeden, Paul Friedman

doi : 10.1093/eurheartj/ehab874

European Heart Journal, Volume 43, Issue 4, 21 January 2022, Pages 271â€“279

This article presents some of the most important developments in the field of digital medicine that have appeared over the last 12 months and are related to cardiovascular medicine. The article consists of three main sections, as follows: (i) artificial intelligence-enabled cardiovascular diagnostic tools, techniques, and methodologies, (ii) big data and prognostic models for cardiovascular risk protection, and (iii) wearable devices in cardiovascular risk assessment, cardiovascular disease prevention, diagnosis, and management. To conclude the article, the authors present a brief further prospective on this new domain, highlighting existing gaps that are specifically related to artificial intelligence technologies, such as explainability, cost-effectiveness, and, of course, the importance of proper regulatory oversight for each clinical implementation.

خرید پکیج و مشاهده آنلاین مقاله

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

Joerg Herrmann, (Chair), Daniel Lenihan, (Co-chair), Saro Armenian, Ana Barac, Anne Blaes, Daniela Cardinale, Joseph Carver, Susan Dent, Bonnie Ky, Alexander R Lyon, Teresa LÃ³pez-FernÃ¡ndez, Michael G Fradley, Sarju Ganatra, Giuseppe Curigliano, Joshua D Mitchell, Giorgio Minotti, Ninian N Lang, Jennifer E Liu, Tomas G Neilan, Anju Nohria, Rupal O'Quinn, Iskra Pusic, Charles Porter, Kerry L Reynolds, Kathryn J Ruddy, Paaladinesh Thavendiranathan, Peter Valent

doi : 10.1093/eurheartj/ehab674

European Heart Journal, Volume 43, Issue 4, 21 January 2022, Pages 280â€“299

The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.

خرید پکیج و مشاهده آنلاین مقاله

Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis

Avirup Guha, Michael G Fradley, Susan F Dent, Neal L Weintraub, Maryam B Lustberg, Alvaro Alonso, Daniel Addison

doi : 10.1093/eurheartj/ehab745

European Heart Journal, Volume 43, Issue 4, 21 January 2022, Pages 300â€“312

The national incidence, risk factors, and associated mortality of atrial fibrillation (AF) in breast cancer patients are unknown.

خرید پکیج و مشاهده آنلاین مقاله

Atrial fibrillation and breast cancer: casual or causal relationship?

Jose L Merino

doi : 10.1093/eurheartj/ehab807

European Heart Journal, Volume 43, Issue 4, 21 January 2022, Pages 313â€“315

خرید پکیج و مشاهده آنلاین مقاله

Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy

Lars Michel, Iris Helfrich, Ulrike Barbara Hendgen-Cotta, Raluca-Ileana Mincu, Sebastian Korste, Simone Maria Mrotzek, Armin Spomer, Andrea Odersky, Christoph Rischpler, Ken Herrmann, Lale Umutlu, Cristina Coman, Robert Ahrends, Albert Sickmann, Stefanie LÃ¶ffek, Elisabeth Livingstone, Selma Ugurel, Lisa Zimmer, Matthias Gunzer, Dirk Schadendorf, Matthias Totzeck, Tienush Rassaf

doi : 10.1093/eurheartj/ehab430

European Heart Journal, Volume 43, Issue 4, 21 January 2022, Pages 316â€“329

Cardiac immune-related adverse events (irAEs) from immune checkpoint inhibition (ICI) targeting programmed death 1 (PD1) are of growing concern. Once cardiac irAEs become clinically manifest, fatality rates are high. Cardio-oncology aims to prevent detrimental effects before manifestation of severe complications by targeting early pathological changes. We therefore aimed to investigate early consequences of PD1 inhibition for cardiac integrity to prevent the development of overt cardiac disease.

خرید پکیج و مشاهده آنلاین مقاله

Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments

Gilda Varricchi, Maria Rosaria Galdiero, Carlo G Tocchetti

doi : 10.1093/eurheartj/ehab584

European Heart Journal, Volume 43, Issue 4, 21 January 2022, Pages 330â€“332

خرید پکیج و مشاهده آنلاین مقاله

Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis

Oliver C Cohen, Andreia Ismael, Babita Pawarova, Richa Manwani, Sriram Ravichandran, Steven Law, Darren Foard, Aviva Petrie, Sevda Ward, Brooke Douglas, Ana Martinez-Naharro, Liza Chacko, Candida Cristina Quarta, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, Philip N Hawkins, Julian D Gillmore, Marianna Fontana, Rodney H Falk, Carol J Whelan, Ashutosh D Wechalekar

doi : 10.1093/eurheartj/ehab507

European Heart Journal, Volume 43, Issue 4, 21 January 2022, Pages 333â€“341

Cardiac involvement, a major determinant of prognosis in AL (light-chain immunoglobulin) amyloidosis, is characterized by an impairment of longitudinal strain (LS%). We sought to evaluate the utility of LS% in a prospectively observed series of patients.

خرید پکیج و مشاهده آنلاین مقاله